Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AIM

AIM ImmunoTech Inc

Dec 12 • 04:00PM ET

0.2130

Dollar change +0.0027
Percentage change 1.28	%

Healthcare • Biotechnology • USA • AMEX

Peers: JNJ LLY PFE AZN MRNA BMY GILD AMGN REGN VRTX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.47	Insider Own	9.11%	Shs Outstand	58.67M	Perf Week	3.85%
Market Cap	13.58M	Forward P/E	-	EPS next Y	-0.37	Insider Trans	4.75%	Shs Float	57.97M	Perf Month	-11.25%
Income	-23.93M	PEG	-	EPS next Q	-0.12	Inst Own	14.13%	Short Float	1.07%	Perf Quarter	-28.26%
Sales	0.19M	P/S	71.47	EPS this Y	42.50%	Inst Trans	-45.96%	Short Ratio	1.39	Perf Half Y	-48.19%
Book/sh	0.05	P/B	4.29	EPS next Y	-7.25%	ROA	-115.46%	Short Interest	0.62M	Perf Year	-56.54%
Cash/sh	0.11	P/C	1.89	EPS next 5Y	-	ROE	-187.58%	52W Range	0.16 - 0.62	Perf YTD	-51.58%
Dividend Est.	-	P/FCF	-	EPS past 5Y	42.86%	ROI	-686.04%	52W High	-65.65%	Beta	-0.40
Dividend TTM	-	Quick Ratio	0.75	Sales past 5Y	-2.98%	Gross Margin	-45.26%	52W Low	30.84%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	0.75	EPS Y/Y TTM	-10.16%	Oper. Margin	-14687.89%	RSI (14)	44.29	Volatility	10.28% 13.81%
Employees	26	Debt/Eq	1.17	Sales Y/Y TTM	-1.55%	Profit Margin	-12594.21%	Recom	1.00	Target Price	2.75
Option/Short	No / Yes	LT Debt/Eq	0.20	EPS Q/Q	60.05%	Payout	-	Rel Volume	2.14	Prev Close	0.21
Sales Surprise	-100.00%	EPS Surprise	0.00%	Sales Q/Q	-23.91%	Earnings	Nov 19 BMO	Avg Volume	447.24K	Price	0.21
SMA20	-1.16%	SMA50	-11.34%	SMA200	-38.18%	Trades		Volume	955,110	Change	1.28%

Dec-12-24 03:00PM	AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members (Business Wire)
09:00AM	AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue (GlobeNewswire)
08:16AM	Kellner Group Announces Support from Another Former AIM Senior Executive (GlobeNewswire)
Dec-11-24 07:30AM	AIMs Clinical Strategy Under Incumbent Board Has Totally Failed (GlobeNewswire)
Dec-10-24 10:20AM	Glass Lewis Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell (Business Wire)
07:30AM	Loading…
07:30AM	Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected (GlobeNewswire)
Dec-06-24 09:15AM	AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment (GlobeNewswire)
08:34AM	Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card (GlobeNewswire)
Dec-05-24 09:00AM	ISS Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan and Dr. William M. Mitchell (Business Wire)
Dec-02-24 08:00AM	AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Groups Nominees to the Board (Business Wire) -5.69%
07:30AM	Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card (GlobeNewswire)
Nov-28-24 08:10AM	AIM ImmunoTech announces cash conservation plan, committment to Ampligen (TipRanks)
Nov-27-24 03:30PM	AIM ImmunoTech Refutes Activist Groups False and Misleading Claims (Business Wire)
08:00AM	AIM ImmunoTech Announces Cash Conservation Plan (Business Wire)
Nov-26-24 07:00AM	Kellner Group Urges Stockholders of AIM Immunotech to Vote Enclosed Gold Card (GlobeNewswire) +5.63%
08:00AM	Loading…
Nov-25-24 08:00AM	AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders (Business Wire)
Nov-20-24 11:50AM	Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board (PR Newswire) +9.29%
Nov-19-24 08:00AM	AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer (GlobeNewswire) -20.57%
07:00AM	Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board (GlobeNewswire)
Nov-16-24 02:01AM	AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
Nov-15-24 07:29AM	AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -11.75%
Nov-06-24 09:00AM	AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast (GlobeNewswire)
Nov-04-24 08:00AM	AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders (Business Wire)
Oct-09-24 09:00AM	AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire)
Oct-03-24 08:45AM	AIM ImmunoTech Granted U.S. Patent for Ampligen for the Treatment of Endometriosis (GlobeNewswire)
Sep-30-24 09:00AM	AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering (GlobeNewswire)
Sep-27-24 08:00AM	AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment (GlobeNewswire)
Sep-19-24 08:00AM	AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer (GlobeNewswire)
Sep-11-24 09:00AM	AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential to Improve the Post-COVID Condition of Fatigue (GlobeNewswire)
Aug-20-24 08:30AM	AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research (GlobeNewswire) +15.32%
07:00AM	Loading…
Aug-16-24 07:00AM	AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-13-24 09:05AM	AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast (GlobeNewswire)
Jul-29-24 09:15AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Jul-24-24 08:50AM	AIM Announces New Positive Data on Ampligen's Anti-Tumor Potential When Used as Part of a Combination Therapy (GlobeNewswire) -7.22%
Jul-03-24 08:55AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +6.49%
Jun-10-24 08:55AM	AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference (GlobeNewswire) -6.35%
Jun-03-24 09:15AM	AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series (GlobeNewswire)
May-31-24 08:30AM	AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering (GlobeNewswire)
May-20-24 09:15AM	AIM ImmunoTech to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-16-24 07:30AM	AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-24 08:50AM	AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast (GlobeNewswire)
May-06-24 08:30AM	AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen (GlobeNewswire)
Apr-29-24 08:55AM	AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer (GlobeNewswire)
Apr-25-24 08:45AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) -5.47%
Apr-18-24 08:45AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Apr-15-24 08:55AM	AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs (GlobeNewswire) -13.74%
Apr-11-24 11:00AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +10.05%
Apr-10-24 08:21AM	AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer (GlobeNewswire) +12.96%
Apr-02-24 07:30AM	AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -8.18%
Mar-28-24 08:05AM	AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference (GlobeNewswire) +6.32%
Mar-26-24 09:05AM	AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast (GlobeNewswire)
Mar-25-24 09:05AM	AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research (GlobeNewswire)
Mar-22-24 08:55AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +16.46%
Mar-20-24 09:25AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Mar-15-24 08:45AM	AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity (GlobeNewswire)
Mar-07-24 08:45AM	AIM ImmunoTech Announces Launch of CEO Corner Platform (GlobeNewswire)
Feb-29-24 08:45AM	AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update (GlobeNewswire)
Feb-14-24 08:55AM	AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZenecas Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire)
Feb-08-24 08:50AM	AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire) -12.64%
Jan-24-24 09:10AM	AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer (GlobeNewswire) -6.88%
Jan-22-24 08:55AM	AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZenecas Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer (GlobeNewswire)
Jan-10-24 08:45AM	AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZenecas Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire)
Jan-05-24 01:32PM	AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting (Business Wire) -8.14%
Jan-03-24 04:05PM	Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied (PR Newswire)
Dec-29-23 08:00AM	Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Boards Determination that Activist Groups Nominations Are Invalid (Business Wire) -8.73%
Nov-28-23 04:30PM	AIM ImmunoTech Provides Update Regarding Annual Meeting (Business Wire) +7.27%
Nov-27-23 09:00PM	AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents (GlobeNewswire)
Nov-21-23 12:00PM	AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire)
Nov-16-23 08:45AM	Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change (PR Newswire)
Nov-15-23 07:30AM	AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update (GlobeNewswire)
Nov-14-23 10:00AM	AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer (GlobeNewswire)
Nov-09-23 08:05AM	AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast (GlobeNewswire) -8.12%
Nov-08-23 08:45AM	AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer (GlobeNewswire)
Nov-06-23 09:25AM	AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders (Business Wire) -8.99%
Oct-30-23 08:55AM	AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) +6.98%
Oct-17-23 08:45AM	AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs (GlobeNewswire) +10.43%
Sep-22-23 09:05AM	AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care (GlobeNewswire)
Sep-11-23 01:00PM	AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer (GlobeNewswire) +7.97%
Sep-05-23 09:05AM	AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-23-23 08:00AM	AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements (Business Wire)
Aug-15-23 06:45AM	AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update (GlobeNewswire) -6.34%
Aug-09-23 09:05AM	AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast (GlobeNewswire)
Aug-08-23 08:05AM	AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire)
Jul-18-23 07:30PM	AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates (GlobeNewswire) +8.43%
06:53AM	Daily Vickers Top Buyers & Sellers for 07/18/2023 (Argus Research)
Jul-10-23 08:05AM	AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire)
Jul-05-23 08:35AM	AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series (GlobeNewswire)
Jun-27-23 11:16AM	AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research (GlobeNewswire) +7.02%
08:45AM	AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZenecas Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire)
Jun-14-23 08:45AM	AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire)
Jun-12-23 08:45AM	AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments (GlobeNewswire)
Jun-07-23 07:11PM	AIMIA ADOPTS SHAREHOLDER RIGHTS PLAN TO PROTECT AGAINST "CREEPING" BIDS AND UNEQUAL TREATMENT OF SHAREHOLDERS (PR Newswire)
May-15-23 08:45AM	AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update (GlobeNewswire)
May-09-23 08:50AM	AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast (GlobeNewswire)
08:46AM	AIMIA ANNOUNCES CLOSING OF BOZZETTO TRANSACTION (PR Newswire)
Apr-20-23 03:56PM	AIMIA'S LARGEST SHAREHOLDER THANKS FELLOW SHAREHOLDERS FOR SUPPORTING CHANGE; MITHAQ EXPLORING ALL OPTIONS TO ENSURE VALIDITY OF RESULTS (PR Newswire)
Apr-12-23 08:35AM	AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB) (GlobeNewswire) +9.15%
07:30AM	AIMIA'S LARGEST SHAREHOLDER REMINDS FELLOW SHAREHOLDERS TO VOTE AGAINST BOARD PRIOR TO PROXY VOTING DEADLINE (PR Newswire)
Apr-10-23 07:30AM	AIMIA'S LARGEST SHAREHOLDER ENCOURAGES FELLOW SHAREHOLDERS TO VOTE AGAINST BOARD (PR Newswire)
Apr-04-23 08:45AM	AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire) +6.05%

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
APPELROUTH STEWART	Director	Dec 02 '24	Buy	0.21	11,112	2,356	355,509	Dec 04 04:05 PM
Equels Thomas K	CEO & President	Nov 20 '24	Buy	0.20	85,000	16,915	1,637,968	Nov 21 12:04 PM
APPELROUTH STEWART	Director	Nov 20 '24	Buy	0.19	81,953	15,817	321,752	Nov 21 12:02 PM
Equels Thomas K	CEO & President	Nov 20 '24	Buy	0.18	60,110	11,000	1,552,968	Nov 20 12:46 PM
Equels Thomas K	CEO & President	Sep 16 '24	Buy	0.30	5,000	1,515	1,493,042	Sep 17 12:05 PM
Equels Thomas K	CEO & President	Sep 13 '24	Buy	0.31	20,000	6,160	1,488,042	Sep 16 03:45 PM
Equels Thomas K	CEO & President	May 06 '24	Buy	0.41	61,729	25,000	778,184	May 07 08:30 AM
Rodino Peter W III	COO, Secretary, Gen. Counsel	May 06 '24	Buy	0.41	30,865	12,500	212,583	May 07 08:30 AM
BRYAN NANCY	Director	Mar 21 '24	Buy	0.39	38,462	15,000	38,462	Mar 22 01:30 PM
APPELROUTH STEWART	Director	Mar 15 '24	Buy	0.33	90,910	30,000	239,765	Mar 18 03:01 PM
Equels Thomas K	CEO & President	Mar 15 '24	Buy	0.33	75,758	25,000	716,455	Mar 18 03:01 PM
Rodino Peter W III	COO, Secretary, Gen. Counsel	Mar 15 '24	Buy	0.33	37,879	12,500	181,718	Mar 18 03:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIM

AIM ImmunoTech Inc

Upgrade your FINVIZ experience